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Receptor-mediated gene delivery employing lectin-
binding specificity 
Raj K. Batra 1, Feng Wang-Johanning 2, Ernst Wagner 3, Robert I. Garver, Jr4-5 and D a v i d T. C u r i e l 4 5 
lThe U n i v e r s i t y of N o r t h C a r o l i n a at Chanel H i l l , School of M e d i a n e , D e p a r t m e n t of M e d i a n e , D i v i s i o n of P u l m o n a r y Diseases, Chapel H i l l , 
N o r t h C a r o l i n a , U S A , 2AThe U n i v e r s i t y of A l a b a m a at B i r m i n g h a m , Gene T h e r a p y P r o g r a m , D e p a r t m e n t of M e d i a n e , B i r m i n g h a m , A l a b a m a , 
U S A , " I n s t i t u t e of M o l e c u l a r P a t h o l o g y , D r - B o h r - G a s s e 7, V i e n n a , A - 1 0 3 0 , A u s t r i a a n d 5 T h e U n i v e r s i t y of A l a b a m a at B i r m i n g h a m , D i v i s i o n 
of P u l m o n a r y and C r i t i c a l Care M e d i a n e , B i r m i n g h a m , A l a b a m a , U S A 
Selective targeting ofmalignant cells will be necessary to 
implement many of the gene therapy strategies being 
designed to combat Cancer. Targeting can be achieved by 
transductional or transcriptional approaches. Transductional 
targeting can be accomplished by exploiting differences in 
the molecules or receptors expressed on the cell surface of 
malignant versus normal cells. Given that malignant cells can 
be distinguished from normal by differences in the expression 
Introduction 
A s methodologies for employing gene therapy for 
Cancer develop, it is becoming clear that specific 
targeting of tumor cells w i l l be essential for successful 
Implementation of many of these approaches. In this 
regard, specific targeting can be achieved by strategies 
that can be grouped in terms of 'transductional' versus 
'transcriptional' approaches. The former approach 
exploits differences in the expression of surface antigens 
and growth factor receptors (e.g. C-erbB-2 gene product 
epidermal growth factor receptor etc.) to target Cancer 
cells. A monoclonal antibody or specific ligand is 
conjugated to the effector toxins, drugs, radionuclides or 
cytokines to be delivered. Targeting is thus achieved by 
specific binding of the vector with cognate cell surface 
molecules. The transcriptional targeting approach 
capitalizes on the Observation that certain tumors are 
capable of differentially and specifically expressing 
selected genes (e.g. carcino-embryonic antigen; a-
fetoprotein; etc.) and thus exploits this distinctive 
pattern of gene regulation. In this regard, aligning 
therapeutic or toxin genes under the control of 
Promoters specific for these selected genes offers a 
potential mode for specific targeting by restricting 
expression to these tumor cell targets. 
Of the vector Systems available for gene transfer, 
molecular conjugates possess unique advantages in 
terms of a design plasticity that potentially permits 
transductional targeting [1-3]. This vector System 
consists of linked ligand and D N A binding domains 
Correspondence: D J . Curiel, UAB Gene Therapy Program, Department of 
Clinical M e d i a n e , Division of Pulmonary and Critical Care Medicine, 
Birmingham, Alabama, LISA 
of cell surface carbohydrates, we hypothesized that 
transductional targeting would be feasible by molecular 
conjugate vectors which achieve cell binding by virtue of 
lectins directed against the cell surface glycocalyx. Wehave 
shown that gene transfer can be accomplished by these 
novel lectin-targeted molecular conjugate vectors and that 
lectin binding specificities may serve as a means for potential 
j targeting of Cancer cells for the purposes of gene therapy. 
which function in an integrated manner to mediate 
efficient gene transfer [4-6]. In this vector strategy, the 
l igand domain permits interaction with cell surface 
receptors that are constituents of cellular internalization 
pathways. This interaction allows the linked D N A to be 
transported into the cell by efficient pathways of 
receptor-mediated endocytosis. Thus, a physiologic 
cellular entry system responsible for macromolecular 
internalization is subverted to accomplish heterologous 
gene transfer. For applications of cell-specific gene 
delivery, it is the flexibility of design of the molecular 
conjugate vectors that permits the possibility of 
achieving targeted gene delivery. In this regard, altering 
the ligand moiety of the construct makes it possible to 
change the vector's b inding specificity, and 
consequently the target cell type for the vector. 
In terms of gene therapy for cancer, unique cancer-
specific ligands are needed to accomplish 
transductional targeting of tumor cells. Although 
various tumors have been shown to overexpress certain 
cell surface receptors, unique receptor pathways have 
not been identified. Despite this potential limitation, 
two classes of agents have been exploited to achieve 
distinction between normal and malignant phenotypes 
based upon differences in cell surface markers: 
monoclonal antibodies and lectins. By virtue of their 
specificity, monoclonal antibodies and lectins can thus 
potentially serve as selective markers for targeting 
malignant cell types. To date, much work has focused 
on the exploitation of antibody specificity to achieve 
tumor targeting. For gene therapy applications, this has 
included the use of antibodies to achieve targeted gene 
delivery i n the context of both viral and non-viral 
vector Systems [7, 8]. A s an alternative, we report here 
data that supports the hypothesis that selective 
©Macmillan Press 1 9 9 4 
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transductional targeting can be achieved by exploiting 
differences in lectin binding to cell surface carbo-
hydrates. Lectins, which are divalent or polyvalent 
ligands that recognize specific glycoconjugates 
expressed on the cell surface [9], have been widely used 
to differentiate phenotypic variants in tissues by virtue 
of their distinctive patterns of expression of surface 
carbohydrates [10-13]. The demonstration that lectins 
can mediate specific binding and endocytosis [14-16] 
underlies their potential to serve as carriers to mediate 
site-specific drug delivery and prompted us to consider 
their use as vectors for directed gene transfer [17]. By 
incorporating lectins as ligands into the design of 
molecular conjugate vectors, we capitalized on 
differences in the cell surface glycocalyx to accomplish 
gene transfer selectively into cells. 
Results 
Gene transfer mediated by lectin-targeted molecular 
conjugates to different cellular targets 
To determine if lectin-targeted conjugates could 
accomplish gene transfer to a specific cell target, a panel 
of conjugates was derived with various lectin-targeting 
moieties and delivered to Lewis hing Carcinoma (LLC) 
cells (Figure 1A). In this analysis, it could be seen that 
the concanavalin (ConA)-containing lectin conjugates 
possessed a greater efficacy of gene transfer into L L C 
cells than molecular conjugates incorporating other 
lectins. In contrast, when the same panel of lectin-
targeted conjugates were delivered to IPEC-J 7 cells, an 
entirely different profile of gene transfer efficacy was 
noted (Figure 1B). This finding suggested that cell 
specific glycoconjugates dictated gene transfer efficiency 
based upon their interaction with specific lectins. Thus, 
it was likely that these differences in surface 
carbohydrates led to the observed differences in profiles 
of D N A transfer efficiency into the two cell types. 
Optimization of lectin-targeted gene transfer 
The conjugates used in the experiments above were 
constructed empirically employing a ratio of 
biotinylated lectin to anti-biotin antibody of 1:1 (i.e. 300 
pmol biotinylated lectin/150 pmol aBAbpL). These 
constructs were hence designated as ' Ix ' conjugates. To 
determine the Optimum ratio of biotinylated lectin to 
antibody-polylysine complexes, conjugates were 
derived varying the amount of biotinylated lectin. 
Therefore, O.lx conjugates had the same amount of 
plasmid containing reporter gene (3.0 |ug D N A ) , but a 
biotinylated lectin/antibody ratio of 1:10. Similarly 0.2x 
conjugates had a fivefold excess of antibody and 0.5x 
conjugates had a biotinylated lect in/aBAbpL ratio of 
1:2. In assessing the gene transfer efficiency of 
conjugates constructed in this fashion, analysis revealed 
that the optimum gene transfer was mediated by 
conjugates that had a biotinylated lectin/aBpL ratio of 
1:10 or 1:5 (Figure 2). Notably, the relative selectivity of 
C o n A conjugates in mediating higher efficiency D N A 
transfer into L L C cells was maintained even when 
conjugates were formulated as O.lx complexes (data not 
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Figure 1 Gene transfer into (A) Lewis lung Carcinoma (LLC) cells and (B) 
I P E C - j , c e l i s by various lectin-targeted molecular conjugate vectors. Cells 
zeere trausduced with lectin-targeted molecular conjugate vectors containing 
3.0 \xg of reporter plasmid DNA pCMVL linked to 3.0 [ig a B A b p L . The 
resultant DNA-aBAbpL comple.x was adjoined to 150 pmol biotinylated 
lectin lo achieve molar equivafents of aBAbpL and biotinylated lect'm and, 
thus, molecular conjugates in the "Ix' configuration. 
shown). This empiric Observation was only determined 
for the L L C cells and their Optimum targeting lectin 
C o n A . It may be that other cellular targets wou ld have 
different optima. Aiternatively, this Observation may 
reflect aspects of the final conjugate configuration that 
would be more generally applicable. 
Specific gene delivery mediated by cell surface-lectin 
interaction 
To establish that gene transfer to L L C cells mediated by 
the lectin-targeted conjugates was a function of the 
256 Gene T h e r a p y 
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Figure 2 Optimization of gene transfer by lectin-targeted molecular 
conjugate vectors. LLC cells were transduced with lectin-targeted molecular 
conjugates containing variable amounts o f C o n A . For these complexes, the 
concentration of the biotinylated lectin was varied between molar equivalents 
of a B A b p L ( l x conjugates) to a 10-fold molar excess of aBAbpL ( O . l x 
conjugates). 
biotinylated lectin, the conjugate components were 
evaluated for their utility for gene transfer (Figure 3). As 
shown, D N A + C o n A or D N A did not accomplish 
detectable reporter gene expression. Although there was 
some non-speeifie transfer of D N A conjugated with 
antibody-polylysine ( D N A + aBAbpL), which has been 
previously noted for p o l y l y s i n e - D N A complexes, the 
efficacy of gene transfer was significantly augmented 
when C o n A was incorporated into the design of the 
construet. Importantly, this gene transfer could be 
attenuated when complexes were constructed 
containing an excess of the ligand, which would serve to 
compete for complex binding. This is consistent with 
our hypothesis that ligand-reeeptor interaction on the 
cell surface between the lectin and its ligand 
carbohydrate triggered conjugate uptake and expression 
of the reporter gene. 
To ensure that incorporation of lectins into this 
design d id not enhance non-speeifie D N A transfer by 
sterically altering conjugate complexes, control 
experiments were performed that demonstrated that 
lectins added to human transferrin-polylysine-DNA 
complexes ( h T f p L - D N A ) had no greater effect on gene 
delivery than h T f p L - D N A complexes alone. Moreover, 
when anti-biotin antibody-polylysine complexes were 
formed with biotinylated C o n A versus non-biotinylated 
C o n A , gene delivery as measured by luciferase gene 
expression was consistently at least fivefold higher with 
conjugate construets that allowed for immunolinkage 
with the lectin. This confirms the crucial nature of the 
physical link between the targeting lectins and the 
polylysine-condensed D N A . 
300,000 r 
200,000 -
100,000 -
0e+0 HBS DNA DNA DNA DNA DNA + + + + ConA aBAbpL aBAbpL aBAbpL 
ConA 2X ConA 
Figure 3 Specific gene transfer mediated by lectin-targeted molecular 
conjugates. LLC cells were transduced with components of the lectin targeted 
molecular conjugates for comparison to the complete conjugate. 
To rule out the the possibility that the differences in 
luciferase gene expression observed with the various 
lectin conjugates were due to increased D N A delivery 
and not due to a secondary action of exogenous lectins 
acting via modulation of signal transduetion, L L C cells 
with a stably integrated luciferase gene driven by the 
C M V promoter/ enhancer were mock-transduced with 
the various biotin-labeled lectins (O.lx and lx) . In this 
analysis, there was no difference in the expression of the 
luciferase gene produet between the groups, suggesting 
the lectins were not acting via transactivation of 
Promoters. Thus, the effect of the various lectins would 
appear to be on the basis of their ability to accomplish 
cellular delivery of the polylysine-complexed D N A . 
Finally, to investigate other methods of linkage of the 
lectin within the complex configuration, molecular 
conjugates were constructed using the streptavidin-
biotin high affinity bond to link biotinylated lectins to 
polylysine. Comparison of gene transfer mediated by 
these lectin-targeted molecular conjugates demonstrated 
that there was no significant difference between gene 
delivery mediated by construets linked by virtue of an 
anti-biotin-biotin relationship versus the streptavidin-
biotin interaction (data not shown). 
Discussion 
Elegant molecular strategies have been proposed for 
destruetion of malignant cells, while sparing normal 
cells. Many of these molecular strategies employ the 
techniques of gene transfer and, for most of these 
strategies, targeted intracellular delivery of 
polynucleotides is a prerequisite for success. Targeting 
can be accomplished by util izing known differences 
between the normal and malignant phenotypes. These 
differences can lie within the expression of tumor 
antigens, or be in the atypical gene regulation of normal 
versus Cancer cells. We have presented data for a 
strategy that exploits cell surface differences of Cancer 
cells to deliver genes selectively into target cells. Lectins, 
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which recognize differences in cell surface architecture, 
have been employed as carriers of toxins and 
chemotherapeutic agents [18-20]. This use of lectins has 
exploited the Observation that malignant transformation 
is frequently associated with characteristic and distinct 
changes in the cell surface glycocalyx. We have utilized 
lectins here as ligands within the context of molecular 
conjugate vectors to achieve gene delivery. We have 
shown not only that lectin binding affinities of different 
cell types can be discriminating, but also that those 
differences can be exploited for transductional targeting 
of selected cell populations. In doing so, we have 
established that lectins, like monoclonal antibodies, have 
the potential for mediating targeted gene delivery. 
However , much needs to be learned about the 
function of cell surface glycoconjugates recognized by 
lectins before we can predictably use lectins as carriers 
of genes. The data reported here demonstrate that at 
least some of the surface carbohydrates recognized by 
lectins may serve as receptors and w i l l allow specific 
endocytosis. In this regard, it is of note that there was 
heterogeneity in terms of gene transfer efficiency 
mediated by targeted lectin molecular conjugate vectors. 
Part of this heterogeneity may be attributed to the 
inconsistent efficacy of chloroquine in mediating 
functional disruption of lysosomes following 
internalization of conjugate vectors. Consequently, a 
significant portion of internalized conjugates was 
probably degraded within the intracellular vesicle 
System. It is also conceivable that immunolinkage of 
biotinylated lectin with the a B A b p L / D N A complexes 
was less than satisfactory and that a component of 
variability observed could be attributed to the inherent 
instability of this antigen-antibody interaction. Perhaps 
a stronger linkage of the ligand with the D N A binding 
domain could serve to overcome this variability, 
although preliminary data suggest otherwise. 
Lastly, before one can generalize regarding the Utility 
of lectin-targeted molecular conjugate vectors, their 
efficacy in mediating gene transfer in primary cell 
populations and, ultimately, in vivo must be demon-
strated. In this regard, it is well recognized that cellular 
lectin-binding specificities change with the microenviron-
ment of the cell, as well as with phenotypic trans-
formation of the cell. Therefore, the selective targeting 
capabilities of a lectin molecular conjugate would reflect 
the experimental design used to assess its targeting 
efficacy. In no circumstance can lectins, or any targeting 
moiety yet developed, reliably discriminate between 
normal and malignant phenotypes with complete 
selectivity and specificity. However, whether the relative 
specificity afforded by recognition of altered glycocalyces 
w i l l suffice in mediating site-specific gene delivery and 
targeting of Cancer cells merits further investigations. 
Materials and methods 
Cells 
L L C cells, a murine cell line derived from a spontan-
eously arising lung Carcinoma, were acquired from the 
American Type Culture Collection (ATCC). IPEC-J 2 cells, 
a non-transformed (primary-passaged) intestinal 
epithelial cell line derived from neonatal piglets [21,22], 
were obtained from Dr Helen Berschneider (NC State 
University, USA). The cell types were plated at a density 
of 1 x 105 cells/well in six-well (3.5 cm) tissue culture 
plates. IPEC-J 2 cells were maintained in Dulbecco's 
modified Eagle rs medium/ F12 (DMEM/F12) 
supplemented with 5% fetal bovine serum (FBS), insulin 
(5 mg/1), transferrin (5 mg/1), selenium (5 jag/1), 
penicillin (10 000 U/1), streptomycin (10 mg/1) (complete 
primary medium for IPEC-J 2 cells). L L C cells were 
maintained in D M E M supplemented with 10% FBS and 
penicillin (10 000 U/1), streptomycin (10 mg/1) (complete 
primary medium for L L C cells). The cells were allowed to 
reach a 50-70% confluency over 24-36 h following 
passage. A t this point, complete primary media was 
replaced with 1.25 ml D M E M supplemented with 2% FBS 
and 100 (IM chloroquine (Sigma) (transfection medium). 
To accomplish gene transfer, 250 p.1 of conjugate Solution 
containing the complexes was added to the transfection 
medium within each well. Four hours later, the trans-
fection medium was removed and the cells washed with 
ice-cold phosphate-buffered saline (PBS, p H 7.5). 
Complete primary medium was replaced onto the cells, 
which were then incubated for 24 h at 37°C prior to their 
harvest for analysis of reporter gene function. 
Conjugate synthesis 
Anti-biotin-polylysine conjugates (aBAbpL) were 
prepared in an analogous fashion as previously described 
[5], To a Solution of 5 mg (31 nmol) of goat anti-biotin 
antibody (Pierce) in 1.5 ml of Hanks' balanced salt 
Solution (HBS; 150 mM N a C l , 20 mM HEPES buffer p H 
7.9), 18 j i l of a 10 mM ethanolic Solution of S-pyridyl-
dithiopropionate (Pharmacia) was added with vigorous 
mixing. After reacting for 2 h, purification was performed 
by gel filtration (Sephadex G25 PD10, Pharmacia; H B S 
buffer p H 7.9) to give 1.8 m l of a Solution containing 31 
nmol antibody modified with 120 nmol dithiopyridine 
linker. This Solution was concentrated to a volume of 0.8 
ml and mixed under an argon atmosphere with a Solution 
of 37 nmol poly(L)lysine. The poly(L)lysine had an 
average chain length of 290 lysine monomers (pLys 2 9 0), 
and was modified with 110 nmol 3-mercaptopropionate 
groups in 360 JLL! 500 mM N a C l , 20 mM HEPES buffer p H 
7.3. The reaction mixture was kept for 48 h at room 
temperature. The mixture was diluted with 1.7 m l 0.5 M 
N a C l and conjugates were isolated by cation-exchange 
chromatography (Pharmacia MonoS 5 x 50 m m column; 
gradient Solution 20-100% buffer B/buffer A / 5 0 mM 
HEPES p H 7.9 and buffer B/buffer A plus 3 M NaCl) . The 
product was eluted at a N a C l concentration of 
approximately 2 M. Pooled product fractions were 
dialyzed against HBS (2 x 500 ml). As checked by 
ultraviolet and ninhydrin assays, 6.4 m l of conjugates 
containing 2.54 mg (17 nmol) anti-biotin antibody, 
modified with 32 nmol polylysine pLys 2 9 0 , were obtained. 
Molecular conjugate gene transfer vectors 
Molecular conjugate vectors containing lectin-targeting 
domains were constructed by immunolinking 
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lectin-polylysine-DNA 
complex 
Figure 4 Construction of l e c t i n - t a r g e t e d molecular conjugate vectors. For 
d e r i v a t i o n of conjugates, plasmid DNA was combined w i t h the 
a n t i b o d y - p o l y l y s i n e a B A b p L . This resulted in the f o r m a l i o n of 
a n t i b o d y - p o l y l y s i n e - D N A complexes. A d d i t i o n of biotin-labeled l e c t i n s 
resulted in the f o r m a t i o n of l e c t i n - p o l y l y s i n e - D N A complexes. 
biotinylated lectins wi th D N A complexed with 
polylysine (Figure 4). The targeting lectins were 
obtained as biotinylated derivatives: b C o n A , b W G A , 
b U E A , b M P A , b P N A , b D B A and bSBA, where C o n A = 
concanavalin A , W G A = wheat germ agglutinin, U E A = 
Ulex europaeus agglutinin I, M P A = Maclura ponifrea 
lectin, P N A = peanut agglutinin, D B A = Dolichos biflorus 
agglutinin, SBA = soybean agglutinin (Vector 
Laboratories, Burlingame, C A , U S A ) . The biotinylated 
lectins were reconstituted according to manufacturer 
recommendations in high performance l iquid 
chromatography (HPLC) purified H 2 0 . 
The monoclonal antibody achieved linkage to the 
targeting lectins by virtue of its specificity for biotin 
(Figure 4). To form complexes, 3.0 |ig of plasmid D N A 
was added to 3.0 ug of aBAbpL in 175 ul HBS (150 mM 
N a C l , 5 mM HEPES p H 7.3), and incubated for 30 min at 
room temperature. Targetable lectin-containing vectors 
were then derived by varying the amount of biotinylated 
lectins added into the above mixture at molar ratios of 
lectin to antibody of 0.1:1.0 and the resultant complexes 
were incubated at room temperature in 250 |il of total 
volume for an additional 30 min. Subsequently, the 
complexes were added to cells in 1.25 m l of low serum, 
chloroquinated transfection media as described above. 
The plasmid p C M V L was used as a reporter of gene 
transfer. In this plasmid, the reporter gene luciferase is 
under the control of the cytomegalovirus (CMV) early 
promoter/enhancer region [23]. Analysis of luciferase 
gene expression in transduced cells was accomplished by 
methods described elsewhere. Luciferase activity was 
detected following normalization of protein content in 
cell lysates 24 h after transfection. A l l transfection experi-
ments were carried out in triplicate or quadruplicate. 
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